DrugPatentWatch Database Preview
Details for Patent: 8,110,225
» See Plans and Pricing
Which drugs does patent 8,110,225 protect, and when does it expire?
Patent 8,110,225 protects RYANODEX and is included in one NDA.
This patent has eight patent family members in five countries.
Summary for Patent: 8,110,225
| Title: | Treatment using dantrolene |
| Abstract: | Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. The low volume, safe for injection formulations of dantrolene have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease. |
| Inventor(s): | Anderson; David (Ashland, VA), Cameransi, Jr.; Benjamin G. (Georgetown, SC), Conklin; Vincent M. (Richmond, VA) |
| Assignee: | Lyotropic Therapeutics, Inc. (Ashland, VA) |
| Application Number: | 12/717,588 |
|
Patent Claim Types: see list of patent claims | Formulation; Compound; Process; Use; |
Drugs Protected by US Patent 8,110,225
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eagle Pharms | RYANODEX | dantrolene sodium | FOR SUSPENSION;INTRAVENOUS | 205579-001 | Jul 22, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,110,225
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2004262507 | Start Trial | |||
| Canada | 2516667 | Start Trial | |||
| European Patent Office | 1435781 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
